国产99久久精品_欧美日本韩国一区二区_激情小说综合网_欧美一级二级视频_午夜av电影_日本久久精品视频

冰島deCODE genetics
　DECODE基因解碼公司成立于1996年，目前員工約480人，總部設在雷克雅未克，是世界上首家利用人類基因圖譜研究相關疾病藥物的企業，在疾病遺傳基因研究領域處于世界領先地位。公司收集并建立人類基因和醫療數據庫，從中研究并找出基因和一般常見病害的關聯，開發基因檢測軟件，研制阻斷性治療藥物，近年來，公司利用冰島及世界各地相對同質的人類資源分析確定了心臟病、糖尿病等50多種常見病的遺傳基因圖譜，相關基因檢測軟件和藥物也在研發中。

Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer. deCODE employs its capabilities to develop DNA-based tests and personal genome scans to better understand individual risk and empower prevention. It also licenses its tests and intellectual property to partners, and provides leading- edge contract services to companies and research institutions around the globe.

Through its CLIA- and CAP-certified laboratory deCODE offers a growing range of risk assessment tests. These include deCODE T2? for type 2 diabetes; deCODE AF? for atrial fibrillation and stroke; deCODE MI? for heart attack; deCODE ProstateCancer? for prostate cancer; deCODE Glaucoma? for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. Through its pioneering personal genome analysis service deCODEme?, the company enables individuals to better understand their risk of dozens of common diseases and to learn about their ancestry and other traits.

deCODE’s therapeutic portfolio includes DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051, a compound targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer’s disease and other conditions. The company intends to partner or directly outlicense these programs for further clinical development.